Sera Prognostics, Anthem Launch Study to Improve Outcomes for Preterm Babies
The PRIME study is designed to provide a blueprint for how healthcare can more effectively identify and manage high-risk pregnancies and reduce preterm birth.
The PRIME study is designed to provide a blueprint for how healthcare can more effectively identify and manage high-risk pregnancies and reduce preterm birth.
The new funding will be used to support commercial expansion of the company's Unity prenatal screening test to all US states as well as research and development for future diagnostics.
The Panorama noninvasive prenatal test is now validated to screen twin pregnancies for zygosity and chromosomal abnormalities.
April 2019’s product spotlight includes immunoassay kits and analyzers from companies such as Fujirebio, Ansh Labs, Tosoh Bioscience, and more.
Read MoreApril 2019’s product spotlight includes immunoassay kits and analyzers from companies such as Fujirebio, Ansh Labs, Tosoh Bioscience, and more.
Read MoreThe test broadens expectant parents’ prenatal testing options to include a safe, noninvasive test tailored to their family’s risk for a specific genetic disease.
Read MoreThe Foresight carrier screen identified 45% more couples at risk for having a child with cystic fibrosis than current guideline-based testing.
Read MoreA novel multiplexing platform called ‘high definition polymerase chain reaction’ brings together widely used, low-cost chemistries and qPCR instrumentation with proprietary data science algorithms to enable streamlined multiplex test development and very affordable test deliverables.
Read MoreThe nationwide study showed worrisome beliefs surrounding cardiac health and disease prevention.
Read MoreEnhanced test improves detection of chromosomal abnormalities by 30%.
Read MoreThe addition allows for easier validation of laboratory-developed tests, documentation of linearity and calibration verification, and verification of reportable range.
Read MoreThe current generation of instruments for in vitro diagnostics is helping to support clinical labs through a strong emphasis on automation.
Read MoreThe ResistancePlus GC molecular diagnostic simultaneously diagnoses N. gonorrhoeae and provides antimicrobial susceptibility information, overcoming many of the issues associated with culture-based methods.
Read MoreHologic’s first-in-category assay, cleared through FDA’s De Novo review process, provides laboratories with a highly sensitive and specific molecular diagnostic method to identify M. genitalium infections and enable effective treatment.
Read MoreThe kit assists laboratories in documenting their linearity and calibration verification for hs-CRP, NT-proBNP, and TnI assays.
Read MoreThe Parsortix system offers the potential to extend NIPT to a wide range of conditions not feasible with existing techniques.
Read MoreThe MenoCheck assay was developed to aid physicians in determining the status of women during menopausal transition.
Read MoreDesigned for use on the company’s Liaison MDx instrument, the highly sensitive assay enables the direct in vitro detection of Group B Streptococcus DNA.
Read More